At the European Cancer Congress (ECC) 2015, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Victoria, Australia, discusses the impact of baseline genetic heterogeneities on progression-free survival in patients with advanced BRAF V600-mutated melanoma treated with cobimetinib plus vemurafenib in the phase 3 coBRIM clinical trial.
Biomarker analysis of coBRIM: Phase 3 trial of cobimetinib plus vemurafenib for advanced melanoma
9th December 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now